Batu Biologics Launches #starvethetumor Crowdfunding Campaign for ValloVax Cancer Immunotherapy

Company is hosting a press conference on May 11th, 2017 to discuss our strategy for ValloVax development

Batu Biologics seeks to #starvethetumor by training your body to attack and kill the tumor vasculature with the ValloVax immunotherapy (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

SAN DIEGO--()--Batu Biologics, an immuno-oncology company dedicated to studying blood vessel formation within tumors, announced today the launch of an equity crowdfunding campaign on EquityNet. This investment offering, which is open to accredited investors, is seeking to fund the upscaling of GMP manufacturing for the ValloVax platform in preparation for our planned Phase I study in advanced lung cancer.

ValloVax is a cellular immunotherapy that trains the body to target and kill pathological blood vessels specific to the tumor. Antigens found preferentially on the tumor endothelium are ideal targets for cancer therapeutics because a.) they are in direct contact with the immune system via the blood and are therefore easier to access b.) an immune response against the tumor vasculature may increase lymphocyte infiltration into tumors and c.) by killing the blood vessels we are seeking to starve the tumor of its food supply.

Angiogenesis is a biological process that is commonly found in all solid tumors. Instead of targeting the tumor itself, which can be a difficult strategy due to cancer’s propensity to mutate, ValloVax trains the body to initiate a cellular and antibody response against several targets associated with tumor angiogenesis. To date, ValloVax has demonstrated strong inhibition of melanoma, lewis lung carcinoma, colorectal cancer, breast cancer, and glioblastoma in animal models. By facilitating better drug delivery and lymphocyte penetration into the tumor, ValloVax may be an ideal candidate for combination therapies with some of the latest immuno-oncology drugs in late stage clinical development or on market.

“Batu has gained significant traction in our partnership efforts for ValloVax in the past couple months, and we are confident that the clearance of our IND application with the Food and Drug Administration will be a critical value inflection point for the company,“ stated Samuel C. Wagner, Chief Executive Officer of Batu Biologics. “We are looking to leverage the FDA’s approval of our IND application to push forward with an international clinical development plan. This is an exciting time for the Company and I would welcome prospective investors to reach out to learn more about our plans for commercialization and the opportunity.”

Batu Biologics is holding a press conference located in the lobby of the ResMed facilities that will be open to the public on Thursday, May 11th, at 10:00AM (PST). The meeting will be located at the following address:

ResMed
9001 Spectrum Center Blvd.
San Diego CA 92123

Visit our campaign today to learn more about Batu Biologics at: www.equitynet.com/c/batu-biologics-inc

Contacts

Batu Biologics Inc
Samuel C. Wagner
President and CEO
Phone: 323-821-1577
Fax: 858-597-7090
samuel.wagner@batubiologics.com
www.batubiologics.com
www.starvethetumor.org

Contacts

Batu Biologics Inc
Samuel C. Wagner
President and CEO
Phone: 323-821-1577
Fax: 858-597-7090
samuel.wagner@batubiologics.com
www.batubiologics.com
www.starvethetumor.org